When was Future Fields founded?

Future Fields was founded in 2017 and raised its 1st funding round 3 years after it was founded.

Where is Future Fields located?

Future Fields is headquartered in Edmonton, Canada.

How many employees does Future Fields have?

As of Dec 31, 2024, the latest employee count at Future Fields is 28.

Is Future Fields a funded company?

Future Fields is a funded company, having raised a total of $21.5M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 25, 2020.

When was the latest funding round of Future Fields?

Future Fields' latest funding was a $***** Series A round on Jun 17, 2025, with participation from 7 investors.

Where does Future Fields rank among its competitors?

Future Fields ranks 3rd amongst 64 active competitors, of which 19 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was LaigoBio, which secured $6.36M in Mar, 2026.

Who are the top competitors of Future Fields?

Future Fields' top competitors include Qkine, Orf Genetics and MarraBio. Among them, LaigoBio secured the most recent funding round in March, 2026.

Future Fields - 2026 Company Profile, Funding & Competitors

Company Details

Biomanufacturing unit for serum-free, bioactive growth factors, and other recombinant proteins. The company has developed a platform called EntoEngine that assists in the production of serum-free medical products. They also offer various products and services related to recombinant proteins.

Key Metrics

Founded Year

2017

Location

Edmonton, Canada

Stage

Series A

Total Funding

$21.5M in 4 rounds

Latest Funding Round

Series A, Jun 17, 2025, $*****

Investors

Bee Partners & 22 more

Ranked

3^rd among 64 active competitors

Employee Count

28 as on Dec 31, 2024

Similar Companies

Qkine & 64 more

View Future Fields' full profile

Future Fields has raised a total funding of $21.5M over 4 rounds. Its first funding round was on Aug 25, 2020. Its latest funding round was a Series A round on Jun 17, 2025 for $*****. 7 investors participated in its latest round. Future Fields has 21 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Future Fields:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 17, 2025	5738307	Series A	5773789	4111176	5333576	5747680
Feb 22, 2023	5743274	Seed	3409946	4479371	7565972	Builders VC & 7 more
Feb 25, 2021	2604077	Seed	6092192	4387897	Bee Partners	Pioneer Fund & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Future Fields's funding rounds and investors

Future Fields' employee count trend

Future Fields has 28 employees as of Dec 24. Here is Future Fields's employee count trend over the years:

Uncover Future Fields' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Future Fields include Qkine, Orf Genetics and MarraBio. Here is the list of Top 10 competitors of Future Fields, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Qkine 2016, Cambridge (United Kingdom), Series A	Developer of animal-free growth factors for life science applications	$8.15M	Parkwalk, Downing Ventures & 17 others	62/100
2nd	Orf Genetics 2001, Kopavogur (Iceland), Series A	Developer of recombinant protein technology	$5.87M	EIC Fund, Europa	56/100
3rd	Future Fields 2017, Edmonton (Canada), Series A	Biomanufacturing unit for serum-free, bioactive growth factors, and other recombinant proteins	$21.5M	Sustainable Development Technology Canada, Coughdrop Capital ... & 21 others	55/100
4th	MarraBio 2011, Newcastle Upon Tyne (United Kingdom), Seed	Biotechnology research company that provides bacterial protein polymers	-	Maven Capital Partners, Northstar Ventures ... & 2 others	48/100
5th	Core Biogenesis 2020, Paris (France), Series A	Provider of UBaaS platform for recombinant protein bioproduction	$14.1M	Entrepreneur First, XAnge & 5 others	46/100
6th	Hunan Zhongsheng Quanpeptide Biotechnology 2017, Zhuzhou (China), Series B	Developer of peptide discovery technology, peptide libraries, and related research products	$47.9M	CDH, Xjsci & 7 others	43/100
7th	Protera 2015, Sunnyvale (United States), Series A	Platform developing protein-based on enzyme technology	$15.8M	Sofinnova Partners, IndieBio & 4 others	42/100
8th	Algenex 2005, Madrid (Spain), Series B	Developer of recombinant biologics for animal and human health	$13.3M	Columbus Venture Partners, Vita Advisory & 1 others	38/100
9th	LaigoBio 2025, Utrecht (Netherlands), Seed	Developer of targeted protein degradation technology for therapeutic applications	$19.8M	Kurma Partners, Curie Capital & 8 others	38/100
10th	Xias Bio 2020, United States, Seed	Developer of recombinant proteins	$250K	IndieBio, SOSV	37/100